<?xml version="1.0" encoding="UTF-8"?>
<feed xmlns="http://www.w3.org/2005/Atom" xmlns:dc="http://purl.org/dc/elements/1.1/">
  <title>ePublications Community:</title>
  <link rel="alternate" href="https://hdl.handle.net/10137/11" />
  <subtitle />
  <id>https://hdl.handle.net/10137/11</id>
  <updated>2019-02-27T19:04:25Z</updated>
  <dc:date>2019-02-27T19:04:25Z</dc:date>
  <entry>
    <title>NT Pnuemococcal vaccination and revaccination guideline July 2018</title>
    <link rel="alternate" href="https://hdl.handle.net/10137/774" />
    <author>
      <name>Centre for Disease Control</name>
    </author>
    <id>https://hdl.handle.net/10137/774</id>
    <updated>2018-07-13T04:01:55Z</updated>
    <summary type="text">Title: NT Pnuemococcal vaccination and revaccination guideline July 2018
Authors: Centre for Disease Control</summary>
  </entry>
  <entry>
    <title>Appendix E2 - Application for Variation to Regular OSD Takeaway USD - Methadone, Buprenorphine</title>
    <link rel="alternate" href="https://hdl.handle.net/10137/867" />
    <author>
      <name>Department of Health</name>
    </author>
    <id>https://hdl.handle.net/10137/867</id>
    <updated>2019-02-12T00:06:50Z</updated>
    <published>0007-01-01T00:00:00Z</published>
    <summary type="text">Title: Appendix E2 - Application for Variation to Regular OSD Takeaway USD - Methadone, Buprenorphine
Authors: Department of Health</summary>
    <dc:date>0007-01-01T00:00:00Z</dc:date>
  </entry>
  <entry>
    <title>Appendix C - Application for authority to prescribe a restricted S8 substance for the treatment of addiction</title>
    <link rel="alternate" href="https://hdl.handle.net/10137/848" />
    <author>
      <name>Department of Health</name>
    </author>
    <id>https://hdl.handle.net/10137/848</id>
    <updated>2019-02-12T00:08:38Z</updated>
    <published>0007-01-01T00:00:00Z</published>
    <summary type="text">Title: Appendix C - Application for authority to prescribe a restricted S8 substance for the treatment of addiction
Authors: Department of Health</summary>
    <dc:date>0007-01-01T00:00:00Z</dc:date>
  </entry>
  <entry>
    <title>Appendix E1 - Application for Variation to Regular OSD Takeaway USD - Buprenorphine, Naloxone</title>
    <link rel="alternate" href="https://hdl.handle.net/10137/853" />
    <author>
      <name>Department of Health</name>
    </author>
    <id>https://hdl.handle.net/10137/853</id>
    <updated>2019-02-12T00:05:44Z</updated>
    <published>0007-01-01T00:00:00Z</published>
    <summary type="text">Title: Appendix E1 - Application for Variation to Regular OSD Takeaway USD - Buprenorphine, Naloxone
Authors: Department of Health</summary>
    <dc:date>0007-01-01T00:00:00Z</dc:date>
  </entry>
  <entry>
    <title>Appendix D - Clinical Assessment for the Level of Supervised Dosing</title>
    <link rel="alternate" href="https://hdl.handle.net/10137/852" />
    <author>
      <name>Department of Health</name>
    </author>
    <id>https://hdl.handle.net/10137/852</id>
    <updated>2019-02-12T00:08:03Z</updated>
    <published>0007-01-01T00:00:00Z</published>
    <summary type="text">Title: Appendix D - Clinical Assessment for the Level of Supervised Dosing
Authors: Department of Health</summary>
    <dc:date>0007-01-01T00:00:00Z</dc:date>
  </entry>
  <entry>
    <title>Code of Practice Schedule 8 Substances - Medicines &amp; Poisons Control</title>
    <link rel="alternate" href="https://hdl.handle.net/10137/897" />
    <author>
      <name>Medicines &amp; Poisons Control</name>
    </author>
    <id>https://hdl.handle.net/10137/897</id>
    <updated>2019-02-12T00:13:53Z</updated>
    <published>0007-01-01T00:00:00Z</published>
    <summary type="text">Title: Code of Practice Schedule 8 Substances - Medicines &amp; Poisons Control
Authors: Medicines &amp; Poisons Control
Description: Code of Practice Schedule 8 Substances - Volume 1 - Medicines &amp; Poisons Control</summary>
    <dc:date>0007-01-01T00:00:00Z</dc:date>
  </entry>
  <entry>
    <title>Applications for Opioid Substitution Therapy (OST) takeaway Unsupervised Dosues (USD) for travel</title>
    <link rel="alternate" href="https://hdl.handle.net/10137/896" />
    <author>
      <name>Department of Health</name>
    </author>
    <id>https://hdl.handle.net/10137/896</id>
    <updated>2019-02-12T00:09:46Z</updated>
    <published>0007-01-01T00:00:00Z</published>
    <summary type="text">Title: Applications for Opioid Substitution Therapy (OST) takeaway Unsupervised Dosues (USD) for travel
Authors: Department of Health
Description: Appendix F - Applications for OSD Takeaway USD for Travel</summary>
    <dc:date>0007-01-01T00:00:00Z</dc:date>
  </entry>
  <entry>
    <title>Elective surgery waiting list – long waits</title>
    <link rel="alternate" href="https://hdl.handle.net/10137/7003" />
    <author>
      <name />
    </author>
    <id>https://hdl.handle.net/10137/7003</id>
    <updated>2018-07-19T00:36:03Z</updated>
    <published>2081-07-19T00:00:00Z</published>
    <summary type="text">Title: Elective surgery waiting list – long waits
Abstract: The percentage of patients on the elective surgery waiting list at the end of month census date who are ready for care and who waited longer than the clinically recommended time for their urgency category.</summary>
    <dc:date>2081-07-19T00:00:00Z</dc:date>
  </entry>
  <entry>
    <title>E-cigarette reforms fact sheet</title>
    <link rel="alternate" href="https://hdl.handle.net/10137/7451" />
    <author>
      <name />
    </author>
    <id>https://hdl.handle.net/10137/7451</id>
    <updated>2019-02-26T00:30:08Z</updated>
    <published>2019-02-26T00:00:00Z</published>
    <summary type="text">Title: E-cigarette reforms fact sheet
Abstract: From 1 July 2019, changes to the Tobacco Control Act come into effect that will change&#xD;
the way e-cigarettes and vaping products can be promoted, sold and used in the Northern&#xD;
Territory.</summary>
    <dc:date>2019-02-26T00:00:00Z</dc:date>
  </entry>
  <entry>
    <title>Q fever: more common than we think, and what this means for prevention.</title>
    <link rel="alternate" href="https://hdl.handle.net/10137/7436" />
    <author>
      <name>Francis, Joshua R</name>
    </author>
    <author>
      <name>Robson, Jenny M</name>
    </author>
    <id>https://hdl.handle.net/10137/7436</id>
    <updated>2019-02-21T04:27:14Z</updated>
    <published>2019-02-18T00:00:00Z</published>
    <summary type="text">Title: Q fever: more common than we think, and what this means for prevention.
Authors: Francis, Joshua R; Robson, Jenny M</summary>
    <dc:date>2019-02-18T00:00:00Z</dc:date>
  </entry>
  <entry>
    <title>Deed of Amendment 2017-18 Service Delivery Agreement Top End Health Service January 2019</title>
    <link rel="alternate" href="https://hdl.handle.net/10137/7386" />
    <author>
      <name />
    </author>
    <id>https://hdl.handle.net/10137/7386</id>
    <updated>2019-02-18T01:40:22Z</updated>
    <published>2019-02-14T00:00:00Z</published>
    <summary type="text">Title: Deed of Amendment 2017-18 Service Delivery Agreement Top End Health Service January 2019
Abstract: An amendment to the Service Agreement for 2017-18.</summary>
    <dc:date>2019-02-14T00:00:00Z</dc:date>
  </entry>
  <entry>
    <title>Retail staff selling tobacco products must be 18 years of age or older</title>
    <link rel="alternate" href="https://hdl.handle.net/10137/7377" />
    <author>
      <name />
    </author>
    <id>https://hdl.handle.net/10137/7377</id>
    <updated>2019-02-13T04:33:48Z</updated>
    <published>2019-02-13T00:00:00Z</published>
    <summary type="text">Title: Retail staff selling tobacco products must be 18 years of age or older
Abstract: All retail staff who sell tobacco products (including e-cigarettes and similar) must be a minimum of&#xD;
18 years of age.</summary>
    <dc:date>2019-02-13T00:00:00Z</dc:date>
  </entry>
  <entry>
    <title>Sale, supply, promotion and use of electroniccigarettes and other devices (vaping)</title>
    <link rel="alternate" href="https://hdl.handle.net/10137/7375" />
    <author>
      <name />
    </author>
    <id>https://hdl.handle.net/10137/7375</id>
    <updated>2019-02-13T04:31:56Z</updated>
    <published>2019-02-13T00:00:00Z</published>
    <summary type="text">Title: Sale, supply, promotion and use of electroniccigarettes and other devices (vaping)
Abstract: Changes under Tobacco Control Act   for e-cigarettes/vaping equipment sellers.</summary>
    <dc:date>2019-02-13T00:00:00Z</dc:date>
  </entry>
  <entry>
    <title>Electornic cigarettes and smoke free requirements</title>
    <link rel="alternate" href="https://hdl.handle.net/10137/7378" />
    <author>
      <name />
    </author>
    <id>https://hdl.handle.net/10137/7378</id>
    <updated>2019-02-13T04:54:52Z</updated>
    <published>2019-02-13T00:00:00Z</published>
    <summary type="text">Title: Electornic cigarettes and smoke free requirements
Abstract: Changes to the Tobacco Act.</summary>
    <dc:date>2019-02-13T00:00:00Z</dc:date>
  </entry>
  <entry>
    <title>10 metre smoke-free buffer areas</title>
    <link rel="alternate" href="https://hdl.handle.net/10137/7374" />
    <author>
      <name />
    </author>
    <id>https://hdl.handle.net/10137/7374</id>
    <updated>2019-02-13T04:29:32Z</updated>
    <published>2019-02-13T00:00:00Z</published>
    <summary type="text">Title: 10 metre smoke-free buffer areas
Abstract: Changes to the Tobacco Act.</summary>
    <dc:date>2019-02-13T00:00:00Z</dc:date>
  </entry>
  <entry>
    <title>Tobacco vending machines must be in child free areas</title>
    <link rel="alternate" href="https://hdl.handle.net/10137/7376" />
    <author>
      <name />
    </author>
    <id>https://hdl.handle.net/10137/7376</id>
    <updated>2019-02-13T04:56:29Z</updated>
    <published>2019-02-13T00:00:00Z</published>
    <summary type="text">Title: Tobacco vending machines must be in child free areas
Abstract: Tobacco vending machines will no longer be allowed in areas of a liquor licensed premises where a&#xD;
child (someone under the age of 18 years old) or children supervised by a parent, guardian or&#xD;
spouse can enter or spend time there.</summary>
    <dc:date>2019-02-13T00:00:00Z</dc:date>
  </entry>
  <entry>
    <title>The barriers to linkage and retention in care for women living with HIV in an high income setting where they comprise a minority group.</title>
    <link rel="alternate" href="https://hdl.handle.net/10137/7437" />
    <author>
      <name>Giles, M L</name>
    </author>
    <author>
      <name>MacPhail, A</name>
    </author>
    <author>
      <name>Bell, C</name>
    </author>
    <author>
      <name>Bradshaw, C S</name>
    </author>
    <author>
      <name>Furner, V</name>
    </author>
    <author>
      <name>Gunathilake, M</name>
    </author>
    <author>
      <name>John, M</name>
    </author>
    <author>
      <name>Krishnaswamy, S</name>
    </author>
    <author>
      <name>Martin, S J</name>
    </author>
    <author>
      <name>Ooi, C</name>
    </author>
    <author>
      <name>Owen, L</name>
    </author>
    <author>
      <name>Russell, D</name>
    </author>
    <author>
      <name>Street, A</name>
    </author>
    <author>
      <name>Post, J J</name>
    </author>
    <id>https://hdl.handle.net/10137/7437</id>
    <updated>2019-02-21T04:27:14Z</updated>
    <published>2019-02-12T00:00:00Z</published>
    <summary type="text">Title: The barriers to linkage and retention in care for women living with HIV in an high income setting where they comprise a minority group.
Authors: Giles, M L; MacPhail, A; Bell, C; Bradshaw, C S; Furner, V; Gunathilake, M; John, M; Krishnaswamy, S; Martin, S J; Ooi, C; Owen, L; Russell, D; Street, A; Post, J J
Abstract: Women comprise a minority population of individuals living with HIV in Australia, and are often poorly represented in research and clinical trials so their needs remain largely unknown. Data suggests that they are diagnosed later than men and start antiretroviral therapy at a lower CD4 cell count. This raises the question whether there are sex specific barriers to linkage and retention in care. This study analyzed 484 surveys received from clinicians collecting demographic, virological, and reproductive health data along with perceived barriers to linkage and retention in care. Most women (67%) were estimated to have been linked into care within 28 days of diagnosis. For women who were not linked into care for more than 28 days, the most commonly reason cited was fear of disclosure to others, followed by fear of disclosure to their partner. The main reasons given for non-retention in care were related to transport, carer responsibilities, financial pressure, health beliefs and concern about stigma or disclosure.</summary>
    <dc:date>2019-02-12T00:00:00Z</dc:date>
  </entry>
  <entry>
    <title>Domains, Elements, and Indicators Guide</title>
    <link rel="alternate" href="https://hdl.handle.net/10137/7351" />
    <author>
      <name />
    </author>
    <id>https://hdl.handle.net/10137/7351</id>
    <updated>2019-02-06T02:00:49Z</updated>
    <published>2019-02-06T00:00:00Z</published>
    <summary type="text">Title: Domains, Elements, and Indicators Guide
Abstract: The Northern Territory Government (NTG) is responsible for maintaining quality and safeguarding requirements during the transition to the National Disability Insurance Scheme (NDIS). This Document is a companion to the NT Quality &amp; Safeguarding Framework 2016.</summary>
    <dc:date>2019-02-06T00:00:00Z</dc:date>
  </entry>
  <entry>
    <title>Clinical perspectives in congenital adrenal hyperplasia due to 3β-hydroxysteroid dehydrogenase type 2 deficiency.</title>
    <link rel="alternate" href="https://hdl.handle.net/10137/7362" />
    <author>
      <name>Al Alawi, Abdullah M</name>
    </author>
    <author>
      <name>Nordenström, Anna</name>
    </author>
    <author>
      <name>Falhammar, Henrik</name>
    </author>
    <id>https://hdl.handle.net/10137/7362</id>
    <updated>2019-02-11T23:52:17Z</updated>
    <published>2019-02-04T00:00:00Z</published>
    <summary type="text">Title: Clinical perspectives in congenital adrenal hyperplasia due to 3β-hydroxysteroid dehydrogenase type 2 deficiency.
Authors: Al Alawi, Abdullah M; Nordenström, Anna; Falhammar, Henrik
Abstract: 3β-hydroxysteroid dehydrogenase type 2 deficiency (3βHSD2D) is a very rare variant of congenital adrenal hyperplasia (CAH) causing less than 0.5% of all CAH. The aim was to review the literature. PubMed was searched for relevant articles. 3βHSD2D is caused by HSD3B2 gene mutations and characterized by impaired steroid synthesis in the gonads and the adrenal glands and subsequent increased dehydroepiandrosterone (DHEA) concentrations. The main hormonal changes observed in patients with 3βHSD2D are elevated ratios of the Δ5-steroids over Δ4-steroids but molecular genetic testing is recommended to confirm the diagnosis. Several deleterious mutations in the HSD3B2 gene have been associated with salt-wasting (SW) crisis in the neonatal period, while missense mutations have been associated with a non-SW phenotype. Boys may have ambiguous genitalia, whereas girls present with mild or no virilization at birth. The existence of non-classic 3βHSD2D is controversial. In an acute SW crisis, the treatment includes prompt rehydration, correction of hypoglycemia, and parenteral hydrocortisone. Similar to other forms of CAH, glucocorticoid and mineralocorticoid replacement is needed for long-term management. In addition, sex hormone replacement therapy may be required if normal progress through puberty is failing. Little is known regarding possible negative long-term consequences of 3βHSD2D and its treatments, e.g., fertility, final height, osteoporosis and fractures, adrenal and testicular tumor risk, and mortality. Knowledge is mainly based on case reports but many long-term outcomes could be presumed to be similar to other types of CAH, mainly 21-hydroxylase deficiency, although in 3βHSD2D it seems to be more difficult to suppress the androgens.</summary>
    <dc:date>2019-02-04T00:00:00Z</dc:date>
  </entry>
  <entry>
    <title>Multiplex Droplet Digital PCR Assay for Quantification of Human T-Cell Leukemia Virus Type 1 Subtype c DNA Proviral Load and T Cells from Blood and Respiratory Exudates Sampled in a Remote Setting.</title>
    <link rel="alternate" href="https://hdl.handle.net/10137/7364" />
    <author>
      <name>Yurick, David</name>
    </author>
    <author>
      <name>Khoury, Georges</name>
    </author>
    <author>
      <name>Clemens, Bridie</name>
    </author>
    <author>
      <name>Loh, Liyen</name>
    </author>
    <author>
      <name>Pham, Hai</name>
    </author>
    <author>
      <name>Kedzierska, Katherine</name>
    </author>
    <author>
      <name>Einsiedel, Lloyd</name>
    </author>
    <author>
      <name>Purcell, Damian</name>
    </author>
    <id>https://hdl.handle.net/10137/7364</id>
    <updated>2019-02-11T23:52:17Z</updated>
    <published>2019-02-01T00:00:00Z</published>
    <summary type="text">Title: Multiplex Droplet Digital PCR Assay for Quantification of Human T-Cell Leukemia Virus Type 1 Subtype c DNA Proviral Load and T Cells from Blood and Respiratory Exudates Sampled in a Remote Setting.
Authors: Yurick, David; Khoury, Georges; Clemens, Bridie; Loh, Liyen; Pham, Hai; Kedzierska, Katherine; Einsiedel, Lloyd; Purcell, Damian
Abstract: During human T-cell leukemia virus type 1 (HTLV-1) infection, the frequency of cells harboring an integrated copy of viral cDNA, the proviral load (PVL), is the main risk factor for progression of HTLV-1-associated diseases. Accurate quantification of provirus by droplet digital PCR (ddPCR) is a powerful diagnostic tool with emerging uses for monitoring viral expression. Current ddPCR techniques quantify HTLV-1 PVL in terms of whole genomic cellular material, while the main targets of HTLV-1 infection are CD4+ and CD8+ T cells. Our understanding of HTLV-1 proliferation and the amount of viral burden present in different compartments is limited. Recently a sensitive ddPCR assay was applied to quantifying T cells by measuring loss of germ line T-cell receptor genes as method of distinguishing non-T-cell from recombined T-cell DNA. In this study, we demonstrated and validated novel applications of the duplex ddPCR assay to quantify T cells from various sources of human genomic DNA (gDNA) extracted from frozen material (peripheral blood mononuclear cells [PBMCs], bronchoalveolar lavage fluid, and induced sputum) from a cohort of remote Indigenous Australians and then compared the T-cell measurements by ddPCR to the prevailing standard method of flow cytometry. The HTLV-1 subtype c (HTLV-1c) PVL was then calculated in terms of extracted T-cell gDNA from various compartments. Because HTLV-1c preferentially infects CD4+ T cells, and the amount of viral burden correlates with HTLV-1c disease pathogenesis, application of this ddPCR assay to accurately measure HTLV-1c-infected T cells can be of greater importance for clinical diagnostics and prognostics as well as monitoring therapeutic applications.</summary>
    <dc:date>2019-02-01T00:00:00Z</dc:date>
  </entry>
</feed>

